Novartis AG

Type: Company
Name: Novartis AG
Nationality: Switzerland
Web Address: http://www.novartis.com
Fact Sheet: Fact Sheet for Novartis India Ltd
First reported 2 hours ago - Updated 8 mins ago - 2 reports

FDA panel backs Novartis' secukinumab for psoriasis

Novartis moved a step closer to US approval for its psoriasis candidate secukinumab after an FDA advisory committee gave unanimous support for the drug yesterday.Secukinumab - currently leading the field among a new class of anti-interleukin-17 (IL-17) ... [Published PMLive - 8 mins ago]
First reported 13 hours ago - Updated 1 hour ago - 2 reports

Novartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™

EAST HANOVER, N.J. , Oct. 21, 2014 /PRNewswire/ -- Today Novartis Pharmaceuticals Corporation launched a new multifaceted multiple sclerosis (MS) awareness campaign aimed to motivate people with relapsing MS to take charge of their disease. The campaign, ... [Published Franklin Credit Management Corporation - 12 hours ago]
First reported 12 hours ago - Updated 2 hours ago - 2 reports

Otonomy Names Yost Chief Commercial Officer

San Diego-based Otonomy Inc., a clinical-stage biopharmaceutical company, announced the appointment of Anthony Yost as chief commercial officer.Yost brings 30 years of experience in pharmaceutical product sales and marketing that includes building and ... [Published San Diego Business Journal - 2 hours ago]
First reported 16 hours ago - Updated 4 hours ago - 4 reports

SomaLogic Announces Novartis Agreement Extension, Equity Investment

Multi-year research agreement for development and application of SomaLogic’s unique proteomics technology to Novartis’ drug discovery and development efforts. ... [Published Technology Networks - 4 hours ago]
First reported 11 hours ago - Updated 4 hours ago - 2 reports

Cambridge biotech launches in hot field of immunotherapy with $12M

A new biotech aimed at a new field of drug development based on using the immune system to fight cancer launched today with $12 million in funding.Unum Therapeutics is being backed by Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. ... [Published Boston Business Journal - 4 hours ago]
First reported Oct 20 2014 - Updated 8 hours ago - 2 reports

Novartis hopes to rev up Theraflu relaunch with TV celeb Nick Cannon

Nick CannonNovartis ( $NVS ) has the face to launch a Theraflu comeback: entertainer Nick Cannon, who's advising Americans to get ready for flu season by getting vaccinated and stocking up on the over-the-counter remedy. The drug was among the consumer ... [Published FiercePharma - 8 hours ago]
First reported Oct 20 2014 - Updated 8 hours ago - 13 reports

FDA Advisory Committee Votes In Favor Of Novartis’ IL-17 Inhibitor

The Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted 7-0 in favor of using Novartis' secukinumab in plaque-psoriasis patientsPage 1 of 2Click Ticker to See live coverageNovartis AG (ADR) ( NVS ) announced yesterday that the Dermatologic ... [Published Bidness Etc - 11 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Novartis Pharms. Corp. v. Par Pharm., Inc.

Case Name: , Civ. No. 11-1077-RGA, 2014 U.S. Dist. LEXIS 121699 (D. Del. Aug. 29, 2014) (Andrews, J.)Drug Product and Patent(s)-in-Suit: Exelon® (rivastigmine); U.S. Patents Nos. 6,335,031 (“the ’031 patent”) and 6,316,023 (“the ’023 patent”)Nature of ... [Published JD Supra - 9 hours ago]
First reported Oct 20 2014 - Updated 19 hours ago - 5 reports

SomaLogic Announces Extension of Multi-Year Collaboration Agreement

SomaLogic, Inc., announced today that Novartis has extended its multi-year research agreement for the development and application of SomaLogic’s unique proteomics technology to Novartis’ drug discovery and development efforts. Novartis…Click to Continue ... [Published Fort Mills Times - Oct 20 2014]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Novartis Drags DRL to Court over Gleevec

HYDERABAD:  Basel-headquartered Novartis Pharmaceuticals Corporation and Novartis AG dragged city-based Dr Reddy's Laboratories Ltd (DRL) and its US subsidiary Dr Reddy's Laboratories Inc to the US court over alleged patent infringement.As per Novartis' ... [Published New Indian Express - 19 hours ago]
First reported Oct 20 2014 - Updated Oct 20 2014 - 6 reports

Novartis Set to Possibly Pullback After Yesterday's Rally of 1.47%

Written on Mon, 10/20/2014 - 6:28pmBy Shiri GuptaNovartis ( NYSE:NVS ) traded in a range yesterday that spanned from a low of $86.49 to a high of $87.99. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $87.24 ... [Published Comtex SmarTrend - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 3 reports

AnaptysBio appoints Marco Londei as chief development officer

Therapeutic antibody specialist AnaptysBio has appointed Marco Londei as chief development officer, leading the preclinical and clinical development of AnaptysBio’s proprietary antibody pipeline.Hamza Suria, president and chief executive officer, said: "Dr ... [Published Pharma Letter - Oct 20 2014]

Quotes

Vas Narasimhan, global head of development at Novartis, said: "There is a need for novel therapies [for psoriasis] as not all treatments are appropriate or effective in every patient. We look forward to working with the FDA as it finalises its review."
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides" which we call human healthhealth care (hhc)
...regulatory filing of the new drug application for AuriPro with the FDA in the first half of 2015," said David Weber, president and CEO of Otonomy. "Tony's expertise in building high-performance commercial teams, and his broad pharmaceutical sales and marketing experience, including products sold in the hospital setting, as well as physician-administered drugs, make him well-suited to lead the commercialization efforts for AuriPro and Otonomy's other product candidates."
"Moderate-to-severe psoriasis is a serious condition where patients suffer from skin lesions that cause itching, pain, and scaling. There is a need for novel therapies, as not all treatments are appropriate or effective in every patient,” said Vas Narasimhan, global head of development for Novartis, in a statement. “Today's recommendation…brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis. We look forward to working with the FDA as it finalizes its review."

More Content

All (2845) | News (2164) | Reports (0) | Blogs (609) | Audio/Video (2) | Fact Sheets (32) | Press Releases (28)
sort by: Date | Relevance
FDA panel backs Novartis' secukinumab for psori... [Published PMLive - 8 mins ago]
Insulet Corporation to Report Third Quarter 201... [Published BioMedReports - 32 mins ago]
Long-Term Safety and Efficacy of Once-Daily Zon... [Published FinanzNachrichten.de - 54 mins ago]
Animal medicine industry investments prime expa... [Published Progressive Dairy - 1 hour ago]
4 ways to make your crowdfunding campaign hit $... [Published Venturebeat - 1 hour ago]
Yeast infection biotech remains private: Viamet... [Published Renaissance Capital - 1 hour ago]
Clinical trials accumulate data for novel anti-... [Published Orthopedics Today - 2 hours ago]
GMP challenges holding back Big Pharma's person... [Published In-Pharmatechnologist - 2 hours ago]
Otonomy Names Yost Chief Commercial Officer [Published San Diego Business Journal - 2 hours ago]
FDA Committee Recommends Novartis Psoriasis Dru... [Published Pharmacy Times - 2 hours ago]
Viamet raises $60M from private funds instead o... [Published Minyanville - 3 hours ago]
Active Stocks: MELA Sciences, Synergy Pharmaceu... [Published BioMedReports - 3 hours ago]
Insead delves into notion of $business as a for... [Published Khaleej Times - 4 hours ago]
SomaLogic Announces Novartis Agreement Extensio... [Published Technology Networks - 4 hours ago]
3 Stocks That Could Surprise This Earnings Season [Published Motley Fool - 4 hours ago]
Cambridge biotech launches in hot field of immu... [Published Boston Business Journal - 4 hours ago]
SomaLogic, Inc. Announces Extension Of Multi-Ye... [Published BioSpace - 5 hours ago]
Regular, frequent physician visits linked to co... [Published Orthopedics Today - 5 hours ago]
The Technology Transfer Block Exemption [Published Out-Law.com - 6 hours ago]
FDA Adds Everolimus to Watch List [Published General Medicine eJournal - 7 hours ago]
MorphoSys gets milestone from Novartis; acquire... [Published Pharma Letter - 7 hours ago]
Tax Inversion Lobbying Booms as Companies Fight... [Published Bloomberg - 7 hours ago]
Swiss Stocks Follow European Markets Sharply Hi... [Published RTTNews.com - 7 hours ago]
Actavis, Sanofi, Boehringer jockey bids for OTC... [Published FiercePharma - 8 hours ago]
Novartis hopes to rev up Theraflu relaunch with... [Published FiercePharma - 8 hours ago]
Prima BioMed : to Host Conference Call & Webcas... [Published 4 Traders - 8 hours ago]
Using music to find inner strength in living wi... [Published LocalSRY.com - 8 hours ago]
Intrasubject Variability of Total IgE Levels in... [Published CHEST - 9 hours ago]
NOVARTIS : Anaptysbio Appoints Dr. Marco Londei... [Published 4 Traders - 9 hours ago]
Novartis Pharms. Corp. v. Par Pharm., Inc. [Published JD Supra - 9 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
4 ways to make your crowdfunding campaign hit $... [Published Venturebeat - 1 hour ago]
GUEST POST Image Credit: Futurama/20th Century Fox You’ve got an amazing product idea, and you’re looking to get it funded. You’re going to need at least a million dollars in capital to make it happen and finding that choice group of investors who’ll ...
Unum Therapeutics scores $12 mln Series A [Published PE Hub Blog - 10 hours ago]
Unum Therapeutics has received $12 million in Series A funding. Fidelity Biosciences and Atlas Venture led the round with participation from Sanofi-Genzyme BioVentures . Headquartered in Cambridge, Mass., Unum Therapeutics is developing cellular ...
Novartis AG (NVS) Showing Bearish Technicals Wi... [Published MarketIntelligenceCenter.com - 12 hours ago]
Novartis AG (NVS) traded between $86.49 and $87.99 before closing at $87.90 Monday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Dec. '14 $87.50 covered call for a net debit of ...
Novartis' plaque psoriasis drug candidate AIN45... [Published PBR - News - 12 hours ago]
The US Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has approved Novartis' AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, to treat moderate-to-severe plaque psoriasis in adult ...
Novartis teams up with multiple sclerosis advoc... [Published PR Newswire: General Business - 13 hours ago]
EAST HANOVER, N.J., Oct. 21, 2014 /PRNewswire/ -- Today Novartis Pharmaceuticals Corporation launched a new multifaceted multiple sclerosis (MS) awareness campaign aimed to motivate people with relapsing MS to take charge of their disease. The campaign, ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Lackluster Day On Wall Street Equals A Mixed Close [Published Wall Street Journal What's News - Jul 15 2014]
TECH PM -- Google and Novartis Team Up [Published Wall Street Journal Tech News Briefing - Jul 15 2014]
1

Press Releases

sort by: Date | Relevance
MorphoSys Announces Clinical Milestone in Ophth... [Published GlobeNewswire: Acquisitions News - Oct 20 2014]
Marketing Application Update, Acquisitions, Col... [Published Financial Services - Oct 10 2014]
Technical Updates on Health Care Sector Stocks ... [Published Financial Services - Oct 06 2014]
Upcoming Presentations, Technical Update, Study... [Published Financial Services - Sep 05 2014]
Pharma Equities Technical Analysis -- Sanofi, A... [Published Financial Services - Aug 26 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.